Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules.
about
Factors contributing to the immunogenicity of meningococcal conjugate vaccinesEfficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriersNeisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal VaccinationConjugation of polysaccharide 6B from Streptococcus pneumoniae with pneumococcal surface protein A: PspA conformation and its effect on the immune responseImmune Responses in U.S. Military Personnel Who Received Meningococcal Conjugate Vaccine (MenACWY) Concomitantly with Other Vaccines Were Higher than in Personnel Who Received MenACWY Alone.Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT.The history of pneumococcal conjugate vaccine development: dose selection.The effect of preexisting anti-carrier immunity on subsequent responses to CRM197 or Qb-VLP conjugate vaccines.Tetanus-diphtheria-pertussis vaccine may suppress the immune response to subsequent immunization with pneumococcal CRM197-conjugate vaccine (coadministered with quadrivalent meningococcal TT-conjugate vaccine): a randomized, controlled trial⋆.Principles of Vaccination.Acid-detoxified Inaba lipopolysaccharide (pmLPS) is a superior cholera conjugate vaccine immunogen than hydrazine-detoxified lipopolysaccharide and induces vibriocidal and protective antibodies.A review of Haemophilus influenzae disease in Europe from 2000-2014: challenges, successes and the contribution of hexavalent combination vaccines.
P2860
Q28828544-62A64894-35B4-4BD9-93AC-44F28524E739Q35756201-3C555C49-AD6C-47E3-B5E4-4F3BCAF896ADQ36265012-B03370B8-FB99-4E86-963E-0FA5BE1AA1C5Q36911270-AFEB53BC-2FF8-4D3D-AAFE-76170534C402Q37163685-CA298754-DD1C-4E88-8DF0-B98C7C3E8B84Q38109830-C94B51FF-64CA-46F1-B256-F047343147B3Q38160248-31092CA4-2944-44EA-AA1F-BE7DFEA59942Q39816694-C58C95C7-B2B8-4743-AF5A-A9F8FBA1DF04Q40265484-80828E97-A9C6-44C8-A27B-C67130F771B6Q40715837-3ACBB66C-3A0B-4997-A9BA-59CE95BCA2FDQ44101270-A5ACD9D3-C471-45E0-94CA-9323AD9D7E0AQ47877094-7FD2FB1A-DF51-421F-8AF2-437CC7B1AB36
P2860
Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Glycoconjugate vaccines and im ...... ons for vaccination schedules.
@en
Glycoconjugate vaccines and im ...... ons for vaccination schedules.
@nl
type
label
Glycoconjugate vaccines and im ...... ons for vaccination schedules.
@en
Glycoconjugate vaccines and im ...... ons for vaccination schedules.
@nl
prefLabel
Glycoconjugate vaccines and im ...... ons for vaccination schedules.
@en
Glycoconjugate vaccines and im ...... ons for vaccination schedules.
@nl
P2093
P2860
P356
P1476
Glycoconjugate vaccines and im ...... ons for vaccination schedules.
@en
P2093
Hans Hallander
Jan Poolman
P2860
P304
P356
10.1586/ERV.11.142
P50
P577
2011-11-01T00:00:00Z